Filing Summary
Business context and reporting period
This Form 8-K was filed by Adagio Therapeutics, Inc. (ticker: ADGI) under Item 5.02. The report date was February 23, 2022, and the filing was signed March 1, 2022. The filing concerns a senior management transition related to the company’s ADG20 COVID-19 clinical programs.
Financial and operating metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material changes
- Lynn Connolly, M.D., Ph.D., resigned as Chief Medical Officer, effective March 25, 2022, to address family obligations.
- Dr. Connolly was expected to remain Chief Medical Officer through the company’s planned analysis of ADG20 data from global Phase 2/3 prevention and treatment trials and to transition her responsibilities.
- Ellie Hershberger, PharmD, Chief Development Officer, was expected to assume permanent responsibility for the company’s clinical development programs.
- The company expected to enter into a consulting agreement with Dr. Connolly; the filing does not provide its terms or compensation.
Outlook, risks, and unusual items
Management’s referenced near-term milestone was the analysis of preliminary safety and efficacy for ADG20 at the 300 mg dose in each global Phase 2/3 trial. The filing does not provide trial results, regulatory outcomes, financial guidance, or a revised development timeline. The leadership transition could create execution and continuity considerations for the clinical programs, although the filing states that transition arrangements were planned.
Investor verification points
- Verify the completion and results of the planned ADG20 Phase 2/3 data analysis.
- Confirm Ms. Hershberger’s assumption of clinical development responsibilities and any subsequent changes in management.
- Review the terms and financial impact of any consulting agreement with Dr. Connolly.
- Note that the supplied filing identifies the registrant as Adagio Therapeutics, Inc.; the request metadata identifies Invivyd, Inc., so the issuer identity should be verified against the relevant SEC record.